- Home
- CMMB vs CWD Comparison
CMMB vs CWD Comparison
Compare CMMB & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- CWD
- Stock Information
- Founded
- CMMB 2004
- CWD 2009
- Country
- CMMB Israel
- CWD United States
- Employees
- CMMB 20
- CWD N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- CMMB Health Care
- CWD Finance
- Exchange
- CMMB Nasdaq
- CWD Nasdaq
- Market Cap
- CMMB 20.9M
- CWD 13.7M
- IPO Year
- CMMB N/A
- CWD 2023
- Fundamental
- Price
- CMMB $1.13
- CWD $0.66
- Analyst Decision
- CMMB Strong Buy
- CWD
- Analyst Count
- CMMB 3
- CWD 0
- Target Price
- CMMB $5.67
- CWD N/A
- AVG Volume (30 Days)
- CMMB 148.4K
- CWD 97.9K
- Earning Date
- CMMB 11-07-2024
- CWD 11-07-2024
- Dividend Yield
- CMMB N/A
- CWD N/A
- EPS Growth
- CMMB N/A
- CWD N/A
- EPS
- CMMB N/A
- CWD N/A
- Revenue
- CMMB N/A
- CWD $72,100,000.00
- Revenue This Year
- CMMB N/A
- CWD N/A
- Revenue Next Year
- CMMB N/A
- CWD $41.65
- P/E Ratio
- CMMB N/A
- CWD N/A
- Revenue Growth
- CMMB N/A
- CWD N/A
- 52 Week Low
- CMMB $0.42
- CWD $0.50
- 52 Week High
- CMMB $2.55
- CWD $1.74
- Technical
- Relative Strength Index (RSI)
- CMMB 28.21
- CWD 56.46
- Support Level
- CMMB $1.29
- CWD $0.53
- Resistance Level
- CMMB $1.59
- CWD $0.76
- Average True Range (ATR)
- CMMB 0.17
- CWD 0.07
- MACD
- CMMB -0.06
- CWD 0.00
- Stochastic Oscillator
- CMMB 4.41
- CWD 61.92
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.